Absence of unspecific innate immune cell activation by GATA-3-specific DNAzymes

Nucleic Acid Therapeutics

Volumn 22, Issue 2, 2012, Pages 117-126

  Dicke, Tanja ^a   Pali Schöll, Isabella ^b   Kaufmann, Andreas ^c   Bauer, Stefan ^c   Renz, Harald ^c   Garn, Holger ^a,c  

^a Sterna Biologicals GmbH and Co KG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNAZYME; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASOPHIL; CATALYSIS; CELL ACTIVATION; CONTROLLED STUDY; CPG ISLAND; DEGRANULATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; GRANULOCYTE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL;

ANIMALS; BASE SEQUENCE; BASOPHILS; CATALYTIC DOMAIN; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DNA, CATALYTIC; DNA, SINGLE-STRANDED; GATA3 TRANSCRIPTION FACTOR; GENES, REPORTER; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LUCIFERASES; MACROPHAGES; MAST CELLS; MICE; MICE, INBRED BALB C; NEUTROPHILS; NF-KAPPA B; PRIMARY CELL CULTURE; RATS; RESPIRATORY BURST; SPLEEN; TOLL-LIKE RECEPTOR 9;

EID: 84859507082     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2011.0294     Document Type: Article

References (38)

1. BAUER, S., KIRSCHNING, C.J., HACKER, H., REDECKE, V., HAUSMANN, S., AKIRA, S., WAGNER, H., and LIPFORD, G.B. (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 98, 9237-9242.
2. BAUM, D.A., and SILVERMAN, S.K. (2008). Deoxyribozymes: useful DNA catalysts in vitro and in vivo. Cell Mol. Life Sci. 65, 2156-2174.
3. BAUM, P., FUNDEL-CLEMENS, K., KREUZ, S., KONTERMANN, R.E., WEITH, A., MENNERICH, D., and RIPPMANN, J.F. (2009). Off-Target Analysis of Control siRNA Molecules Reveals Important Differences in the Cytokine Profile and Inflammation Response of Human Fibroblasts. Oligonucleotides 20, 17-26.
4. BOUCHARD, P.R., HUTABARAT, R.M., and THOMPSON, K.M. (2010). Discovery and development of therapeutic aptamers. Annu. Rev. Pharmacol. Toxicol. 50, 237-257.
5. BREAKER, R.R., and JOYCE, G.F. (1994). A DNA enzyme that cleaves RNA. Chem. Biol. 1, 223-229.
6. BREAKER, R.R., and JOYCE, G.F. (1995). A DNA enzyme with Mg(2 +) -dependent RNA phosphoesterase activity. Chem. Biol. 2, 655-660.
7. BUNKA, D.H., and STOCKLEY, P.G. (2006). Aptamers come of age - at last. Nat. Rev. Microbiol. 4, 588-596.
8. BURCKSTUMMER, T., BAUMANN, C., BLUML, S., DIXIT, E., DURNBERGER, G., JAHN, H., PLANYAVSKY, M., BILBAN, M., COLINGE, J., BENNETT, K.L., and SUPERTI-FURGA, G. (2009). An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol. 10, 266-272.
9. BUTTERFIELD, J.H., WEILER, D., DEWALD, G., and GLEICH, G.J. (1988). Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 12, 345-355.
10. CAMPBELL, J.D., CHO, Y., FOSTER, M.L., KANZLER, H., KACHURA, M.A., LUM, J.A., RATCLIFFE, M.J., SATHE, A., LEISHMAN, A.J., BAHL, A., MCHALE, M., COFFMAN, R.L., and HESSEL, E.M. (2009). CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. J. Clin. Invest. 119, 2564-2576.
11. CROOKE, S.T. (1998). Vitravene-another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 8, vii-viii.
12. DASS, C.R., and CHOONG, P.F. (2010). Sequence-related offtarget effect of Dz13 against human tumor cells and safety in adult and fetal mice following systemic administration. Oligonucleotides 20, 51-60.
13. ECCLESTON, E., LEONARD, B.J., LOWE, J.S., and WELFORD, H.J. (1973). Basophilic leukaemia in the albino rat and a demonstration of the basopoietin. Nat. New Biol. 244, 73-76.
14. FAHMY, R.G., WALDMAN, A., ZHANG, G., MITCHELL, A., TEDLA, N., CAI, H., GECZY, C.R., CHESTERMAN, C.N., PERRY, M., and KHACHIGIAN, L.M. (2006). Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat. Biotechnol. 24, 856-863.
15. FONSECA, D.E., and KLINE, J.N. (2009). Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv. Drug Deliv. Rev. 61, 256-262.
16. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
17. GUPTA, G.K., and AGRAWAL, D.K. (2010). CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. BioDrugs 24, 225-235.
18. HESSEL, E.M., CHU, M., LIZCANO, J.O., CHANG, B., HERMAN, N., KELL, S.A., WILLS-KARP, M., and COFFMAN, R.L. (2005). Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J. Exp. Med. 202, 1563-1573.
19. HORNUNG, V., and LATZ, E. (2010). Intracellular DNA recognition. Nat. Rev. Immunol. 10, 123-130.
20. ISAKA, Y., NAKAMURA, H., MIZUI, M., TAKABATAKE, Y., HORIO, M., KAWACHI, H., SHIMIZU, F., IMAI, E., and HORI, M. (2004). DNAzyme for TGF-beta suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 66, 586-590.
21. IWASAKI, A., and MEDZHITOV, R. (2004). Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987-995.
22. KLEINMAN, M.E., YAMADA, K., TAKEDA, A., CHANDRASEKARAN, V., NOZAKI, M., BAFFI, J.Z., ALBUQUERQUE, R.J., YAMASAKI, S., ITAYA, M., PAN, Y., et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597.
23. OLKER, C., SIESE, A., STUMPF, S., MULLER, B., GEMSA, D., and GARN, H. (2004). Impaired superoxide radical production by bronchoalveolar lavage cells from NO(2)-exposed rats. Free Radic. Biol. Med. 37, 977-987.
24. RALPH, P., and NAKOINZ, I. (1975). Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line. Nature 257, 393-394.
25. RAYBURN, E.R., and ZHANG, R. (2008). Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov. Today 13, 513-521.
26. REICH, S.J., FOSNOT, J., KUROKI, A., TANG, W., YANG, X., MAGUIRE, A.M., BENNETT, J., and TOLENTINO, M.J. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216.
27. ROBBINS, M., JUDGE, A., AMBEGIA, E., CHOI, C., YAWORSKI, E., PALMER, L., MCCLINTOCK, K., and MACLACHLAN, I. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum. Gene Ther. 19, 991-999.
28. ROBBINS, M., JUDGE, A., and MACLACHLAN, I. (2009). siRNA and innate immunity. Oligonucleotides 19, 89-102.
29. SANTELIZ, J.V., VAN NEST, G., TRAQUINA, P., LARSEN, E., and WILLS-KARP, M. (2002). Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109, 455-462.
30. SANTORO, S.W., and JOYCE, G.F. (1997). A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U. S. A. 94, 4262-4266.
31. SCHOLL, I., ACKERMANN, U., OZDEMIR, C., BLUMER, N., DICKE, T., SEL, S., SEL, S., WEGMANN, M., SZALAI, K., KNITTELFELDER, R., et al. (2007). Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring. FASEB J. 21, 1264-1270.
32. SEL, S., WEGMANN, M., DICKE, T., SEL, S., HENKE, W., YILDIRIM, A.O., RENZ, H., and GARN, H. (2008). Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J. Allergy Clin. Immunol. 121, 910-916.
33. SENTI, G., JOHANSEN, P., HAUG, S., BULL, C., GOTTSCHALLER, C., MULLER, P., PFISTER, T., MAURER, P., BACHMANN, M.F., GRAF, N., and KUNDIG, T.M. (2009). Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin. Exp. Allergy 39, 562-570.
34. SUNDSTROM, C., and NILSSON, K. (1976). Establishment and characterization of a human histiocytic lymphoma cell line (U- 937). Int. J. Cancer 17, 565-577.
35. TAKAOKA, A., WANG, Z., CHOI, M.K., YANAI, H., NEGISHI, H., BAN, T., LU, Y., MIYAGISHI, M., KODAMA, T., HONDA, K., et al. (2007). DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501-505.
36. WAGNER, H., and BAUER, S. (2006). All is not Toll: new pathways in DNA recognition. J. Exp. Med. 203, 265-268.
37. ZAMECNIK, P.C., and STEPHENSON, M.L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 75, 280-284.
38. ZHU, J., YAMANE, H., COTE-SIERRA, J., GUO, L., and PAUL, W.E. (2006). GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 16, 3-10.